Company news

Crinetics Pharmaceuticals, Inc. news in 2026

Crinetics Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

August 3, 2026

Vertex to Acquire Crinetics Pharmaceuticals

July 5, 2026

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

June 14, 2026

Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities

June 2, 2026

Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations

June 2, 2026

Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

May 22, 2026

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

May 7, 2026

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

April 27, 2026

Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer

April 15, 2026

Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

April 7, 2026

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

March 25, 2026

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

March 25, 2026

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 26, 2026

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 25, 2026

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

February 5, 2026

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

January 25, 2026

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

January 22, 2026

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 12, 2026

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

January 6, 2026

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

January 4, 2026

Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

January 4, 2026

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

January 3, 2026

Calls in 2026

Decks in 2026